Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina

Chahla, Rossana Elena; Ruiz, Luis Medina; Ortega, Eugenia Silvana; Rn, Marcelo F Morales; Barreiro, Francisco; George, Alexia; Rn, Cesar Mancilla; Amato, Simona; Barrenechea, Guillermo; Goroso, Daniel Gustavo; Bruno, María Peral de

doi:10.1097/mjt.0000000000001433

Cited by 22 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As características dos estudos incluídos nesta revisão sistemática estão resumidas na Tabela 1. Nove artigos foram elegíveis para inclusão no presente estudo, consistindo em quatro ensaios clínicos randomizados (Blum et al, 2021;Chahla et al, 2021;Rocco et al, 2021;Sayed et al, 2021), um ensaio clínico não randomizado (Elalfy et al, 2021), uma coorte retrospectiva (Morgenstern et al, 2021), um estudo transversal (López et al, 2021), uma série de casos (Meneses e um relato de caso (Chérrez-Ojeda et al, 2020). Os artigos são procedentes da Argentina (n = 1) (Chahla et al, 2021), Brasil (n = 2) (Blum et al, 2021;Rocco et al, 2021), Egito (n = 2) (Elalfy et al, 2021;Sayed et al, 2021), Equador (n = 1) (Chérrez-Ojeda et al, 2020), México (n = 2) (López et al, 2021;Meneses Calderón et al, 2020) e República Dominicana (n = 1) (Morgenstern et al, 2021).…”

Section: Fonte: Autores (2022)unclassified

“…Nove artigos foram elegíveis para inclusão no presente estudo, consistindo em quatro ensaios clínicos randomizados (Blum et al, 2021;Chahla et al, 2021;Rocco et al, 2021;Sayed et al, 2021), um ensaio clínico não randomizado (Elalfy et al, 2021), uma coorte retrospectiva (Morgenstern et al, 2021), um estudo transversal (López et al, 2021), uma série de casos (Meneses e um relato de caso (Chérrez-Ojeda et al, 2020). Os artigos são procedentes da Argentina (n = 1) (Chahla et al, 2021), Brasil (n = 2) (Blum et al, 2021;Rocco et al, 2021), Egito (n = 2) (Elalfy et al, 2021;Sayed et al, 2021), Equador (n = 1) (Chérrez-Ojeda et al, 2020), México (n = 2) (López et al, 2021;Meneses Calderón et al, 2020) e República Dominicana (n = 1) (Morgenstern et al, 2021). Research, Society and Development, v. 11, n. 8, e43511831090, Quanto ao uso dos medicamentos, três estudos avaliaram a ivermectina para tratamento ou profilaxia da COVID-19 (Chahla et al, 2021;Elalfy et al, 2021;Morgenstern et al, 2021), sendo que apenas um estudo avaliou seu uso de forma isolada (Morgenstern et al, 2021).…”

Section: Fonte: Autores (2022)unclassified

“…Os artigos são procedentes da Argentina (n = 1) (Chahla et al, 2021), Brasil (n = 2) (Blum et al, 2021;Rocco et al, 2021), Egito (n = 2) (Elalfy et al, 2021;Sayed et al, 2021), Equador (n = 1) (Chérrez-Ojeda et al, 2020), México (n = 2) (López et al, 2021;Meneses Calderón et al, 2020) e República Dominicana (n = 1) (Morgenstern et al, 2021). Research, Society and Development, v. 11, n. 8, e43511831090, Quanto ao uso dos medicamentos, três estudos avaliaram a ivermectina para tratamento ou profilaxia da COVID-19 (Chahla et al, 2021;Elalfy et al, 2021;Morgenstern et al, 2021), sendo que apenas um estudo avaliou seu uso de forma isolada (Morgenstern et al, 2021). Em contrapartida, sete estudos avaliaram o uso da nitazoxanida para tratamento ou profilaxia da doença (Blum et al, 2021;Chérrez-Ojeda et al, 2020;Elalfy et al, 2021;López et al, 2021;Meneses Calderón et al, 2020;Rocco et al, 2021;Sayed et al, 2021), dos quais três consideraram seu uso isolado (Blum et al, 2021;Meneses Calderón et al, 2020;Rocco et al, 2021).…”

Section: Fonte: Autores (2022)unclassified

See 2 more Smart Citations

Uso de ivermectina e nitazoxanida para tratamento e profilaxia da COVID-19: Uma revisão sistemática

Santos

Neto²,

Rocha³

et al. 2022

RSD

View full text Add to dashboard Cite

Objetivos: Revisar sistematicamente a literatura científica acerca das evidências sobre o uso de ivermectina e nitazoxanida como tratamento e profilaxia para a COVID-19. Metodologia: Esta revisão sistemática foi desenvolvida de acordo com o Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). As bases bibliográficas PubMed, Lilacs e SciELO foram pesquisadas em 14 de outubro de 2021 para identificar estudos que avaliaram o uso de ivermectina e nitazoxanida para tratamento ou profilaxia de casos confirmados ou suspeitos de COVID-19. Resultados: Foram recuperados 105 artigos, dos quais 9 foram incluídos para a revisão final, quatro ensaios clínicos randomizados, um ensaio clínico não randomizado, uma coorte retrospectiva, um estudo transversal, uma série de casos e um relato de caso. A maioria dos estudos eram do Brasil, Egito e México, avaliaram a nitazoxanida e abordaram o tratamento da doença. Conclusões: Não existem evidências científicas suficientemente robustas para apoiar o tratamento e/ou a profilaxia com a ivermectina e nitazoxanida para a COVID-19. Apesar dos resultados encontrados não apontarem um risco aumentado de eventos adversos aos medicamentos analisados, não se deve presumir que seu uso é isento de riscos e estes devem ser usados de maneira racional.

show abstract

Section: Fonte: Autores (2022)unclassified

See 1 more Smart Citation

Uso de ivermectina e nitazoxanida para tratamento e profilaxia da COVID-19: Uma revisão sistemática

Santos

Neto²,

Rocha³

et al. 2022

RSD

View full text Add to dashboard Cite

show abstract

“…Four studies met the criteria and were included in the meta-analysis (Table 1). Two studies were conducted in Egypt 12,13 , one in Argentina 14 and one in Singapore 15 . The studies included a range of participants, for example -high risk migrant workers living in dormitories, healthcare personnel and close contacts.…”

Section: Quality Assessmentmentioning

confidence: 99%

“…The trial conducted by Chahla et al (Argentina), was rated as having a high risk of bias 14 . Following a comprehensive assessment some discrepancies were identi ed in the reported results.…”

Section: Quality Assessmentmentioning

confidence: 99%

Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud

Hill¹

2021

Preprint

View full text Add to dashboard Cite

Background Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials. Objectives To conduct a meta-analysis with randomised controlled trials of ivermectin for the prevention of COVID-19, while controlling for the quality of data. Methods We conducted a sub-group analysis based on the quality of randomised controlled trials evaluating ivermectin for the prevention of COVID-19. Quality was assessed using the Cochrane Risk of Bias measures (RoB 2) and additional checks on raw data, where possible. Results Four studies were included in the meta-analysis. One was rated as being potentially fraudulent, two as having a high risk of bias and one as having some concerns for bias. Ivermectin did not have a significant effect on preventing RT-PCR confirmed COVID-19 infection. Ivermectin had a significant effect on preventing symptomatic COVID-19 infection in one trial with some concerns of bias, but this result was based on post-hoc analysis of a multi-arm study. Conclusions This meta-analysis demonstrates that the currently available randomised trials evaluating ivermectin for the prevention of COVID-19 are insufficient and of poor quality.

show abstract

Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles

et al. 2023

View full text Add to dashboard Cite

ImportanceRandomized clinical trials (RCTs) on COVID-19 are increasingly being posted as preprints before publication in a scientific, peer-reviewed journal.ObjectiveTo assess time to journal publication for COVID-19 RCT preprints and to compare differences between pairs of preprints and corresponding journal articles.Evidence ReviewThis systematic review used a meta-epidemiologic approach to conduct a literature search using the World Health Organization COVID-19 database and Embase to identify preprints published between January 1 and December 31, 2021. This review included RCTs with human participants and research questions regarding the treatment or prevention of COVID-19. For each preprint, a literature search was done to locate the corresponding journal article. Two independent reviewers read the full text, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2 tool. Time to publication was analyzed using a Cox proportional hazards regression model. Differences between preprint and journal article pairs in terms of outcomes, analyses, results, or conclusions were described. Statistical analysis was performed on October 17, 2022.FindingsThis study included 152 preprints. As of October 1, 2022, 119 of 152 preprints (78.3%) had been published in journals. The median time to publication was 186 days (range, 17-407 days). In a multivariable model, larger sample size and low risk of bias were associated with journal publication. With a sample size of less than 200 as the reference, sample sizes of 201 to 1000 and greater than 1000 had hazard ratios (HRs) of 1.23 (95% CI, 0.80-1.91) and 2.19 (95% CI, 1.36-3.53) for publication, respectively. With high risk of bias as the reference, medium-risk articles with some concerns for bias had an HR of 1.77 (95% CI, 1.02-3.09); those with a low risk of bias had an HR of 3.01 (95% CI, 1.71-5.30). Of the 119 published preprints, there were differences in terms of outcomes, analyses, results, or conclusions in 65 studies (54.6%). The main conclusion in the preprint contradicted the conclusion in the journal article for 2 studies (1.7%).Conclusions and RelevanceThese findings suggest that there is a substantial time lag from preprint posting to journal publication. Preprints with smaller sample sizes and high risk of bias were less likely to be published. Finally, although differences in terms of outcomes, analyses, results, or conclusions were observed for preprint and journal article pairs in most studies, the main conclusion remained consistent for the majority of studies.

show abstract

Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina

Cited by 22 publications

References 18 publications

Uso de ivermectina e nitazoxanida para tratamento e profilaxia da COVID-19: Uma revisão sistemática

Uso de ivermectina e nitazoxanida para tratamento e profilaxia da COVID-19: Uma revisão sistemática

Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud

Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles

Contact Info

Product

Resources

About